Pembrolizumab: a beacon of hope for clear-cell renal-cell carcinoma patients post-nephrectomy
Bibliographic record
Abstract
Dear Editor, Clear-cell renal-cell carcinoma (ccRCC) is the most common type of renal cancer1,2. In ccRCC, there is a high risk of metastasis and recurrence1,3. Extensive research is being done to develop novel therapies for ccRCC. A shining example of such progress is the development and subsequent approval of adjuvant pembrolizumab (Fig. 1) for the adjuvant treatment of clear-cell renal-cell carcinoma4. This innovative therapy, as demonstrated in the pivotal KEYNOTE-564 trial, offers not just a lifeline but a tangible improvement in survival outcomes for patients who have undergone surgery for this aggressive cancer5.Figure 1: Prescribing information of adjuvant pembrolizumab. [Created with BioRender.com].Pembrolizumab, an immune checkpoint inhibitor that promotes the body’s immune response against cancer cells, has shown promising results in the recent phase 3, double-blind, randomized, placebo-controlled trial involving 994 participants at increased risk of recurrence post-surgery4. Those treated with 200 mg pembrolizumab for up to 17 cycles experienced a significant improvement in both disease-free and overall survival compared to those who received a placebo4. Specifically, the estimated overall survival rate at 48 months was an impressive 91.2% in the pembrolizumab group versus 86.0% in the placebo group. The success of pembrolizumab in extending survival in renal-cell carcinoma patients post-surgery signifies a notable advancement in oncology. It represents the ongoing shift towards precision medicine, where treatments are increasingly based on individual patient characteristics and the genetic makeup of their tumors. Furthermore, the trial’s findings could potentially set the stage for exploring the efficacy of pembrolizumab in other types of cancer, thereby broadening its applicability and benefit to a larger cohort of patients. While the efficacy of pembrolizumab paints a hopeful picture, it is accompanied by an increased incidence of serious adverse events. About one in five patients treated with pembrolizumab experienced serious side effects compared to approximately one in ten receiving the placebo4. These figures highlight a considerable trade-off between the benefits of extended survival and the risk of severe side effects. This underscores the necessity for oncologists and patients to engage in thorough discussions about the potential risks and benefits of this treatment, ensuring that the decision to proceed with pembrolizumab is well-informed and tailored to the individual patient’s health status and treatment preferences. In conclusion, pembrolizumab has cemented its role as a cornerstone of therapy for patients with clear-cell renal-cell carcinoma after surgery. While the increased risk of adverse events cannot be overlooked, the substantial survival benefit underscores the importance of this therapeutic breakthrough. As we advance, continuous research and patient monitoring will be paramount in optimizing the use of pembrolizumab, aiming for maximal benefit while mitigating risks. In the grand scheme of cancer treatment, pembrolizumab stands out as a beacon of hope, guiding us toward a future where cancer can be confronted more effectively and with renewed vigor. Ethical approval Not applicable. Consent Not applicable. Source of funding Not applicable. Author contribution A.A.: conceptualization, project administration, supervision, validation, writing—original draft and writing—review and editing. G.T.B.: validation, writing—original draft and writing—review and editing. P.S.: supervision, validation, writing—review and editing. R.K.S.: supervision, validation, writing—review and editing. D.S.: supervision, validation, writing—review and editing. M.A.: supervision, validation, writing—review and editing. M.N.K.: supervision, validation, writing—review and editing. S.G.: supervision, validation, writing—review and editing. Q.S.Z.: supervision, validation, writing—review and editing. S.R.: supervision, validation, writing—review and editing. Conflicts of interest disclosure The authors declare no conflicts of interests. Research registration unique identifying number (UIN) Not applicable. Guarantor Ayush Anand. Data availability statement Not applicable. Provenance and peer review Not commissioned, externally peer-reviewed.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".